Centanafadine (Simtriyo) for ADHD: What the Label Actually Says

Why I Am Writing This Now

I published a review of the modern ADHD pharmacopeia on this site in May 2026, and in it I wrote that centanafadine, if approved, "would be the first non-stimulant ADHD medication with direct dopaminergic activity." That was the consensus reading at the time. It was also wrong, and I want to correct it directly, because the correction is more clinically useful than the original claim.

My research program at Columbia is concerned with ADHD pharmacology and the real-world consequences of treatment and non-treatment — including a 2025 JAMA Psychiatry analysis of stimulant treatment and functional outcomes in a cohort of 247,420 individuals, and a 2019 JAMA Network Open study of antipsychotic-before-stimulant prescribing in youth. That work makes me unusually interested in the gap between how a drug is described in the trade press and what its label actually commits to. With centanafadine, that gap is wide.

What follows is a read of the approved prescribing information, not of the press release. Every number below comes from the label.

The Central Surprise: This Is a Stimulant

Section 1 of the prescribing information opens with this: "SIMTRIYO is a norepinephrine-dopamine-serotonin reuptake inhibitor and central nervous system stimulant indicated for the treatment of ADHD."

The phrase "central nervous system stimulant" is not incidental language. It carries specific consequences that run through the entire label:

• The controlled substance schedule is listed as pending DEA review. The label's "Initial U.S. Approval" field is literally blank — annotated as pending scheduling.
• There is a boxed warning for abuse, misuse, and addiction, phrased in the same terms used for methylphenidate and amphetamine products: "Abuse of central nervous system (CNS) stimulants, including SIMTRIYO, can lead to the development of a substance use disorder, including addiction."
• Prescribers are instructed to assess abuse risk before initiating, to counsel families on locked storage and proper disposal, and to reassess risk and monitor for signs of misuse throughout treatment.

For years, the appeal of centanafadine in clinical conversation was precisely that it might sidestep all of this. A dopaminergic agent without Schedule II handcuffs would have been a genuinely significant addition — especially for patients with substance use histories, for families anxious about diversion, and in the context of the recurring stimulant supply shortages that have made Schedule II prescribing operationally miserable. That drug did not arrive.

The Human Abuse-Liability Data

The reason for the classification is in Section 9.2, and it is the most striking part of the label. Two human abuse-potential studies were conducted in people with a history of recreational stimulant use.

In the first study, single doses of immediate-release centanafadine 400 mg and 800 mg (roughly 2 and 4 times the adult starting dose) produced Drug Liking scores on a visual analog scale that were greater than placebo and not statistically significantly less than the scores produced by amphetamine 40 mg. The 800 mg dose likewise produced Drug Liking not statistically significantly less than lisdexamfetamine 150 mg. Centanafadine produced elevated mood in 9 to 12% of subjects, compared with 7% for amphetamine and 12% for lisdexamfetamine.

In the second study, centanafadine 200 mg, 400 mg, and 800 mg produced Drug Liking greater than placebo but less than amphetamine 15 mg and 30 mg. Euphoric mood occurred in 17 to 30% of centanafadine subjects, comparable to 19 to 35% with amphetamine.

The label's conclusion is unhedged: "These human data demonstrate that centanafadine has abuse potential."

Two observations for clinicians. First, the doses tested were supratherapeutic and used an immediate-release formulation, which is the standard design for abuse-liability work and is deliberately unfavorable to the drug — the marketed product is an extended-release capsule, and slower absorption meaningfully blunts liking. Second, and notwithstanding that, a signal statistically indistinguishable from amphetamine at any dose is not a subtle finding, and it is not the profile of atomoxetine or viloxazine, neither of which carries an abuse warning at all.

The One Real Consolation: No Physical Dependence

Section 9.3 contains the label's most genuinely favorable finding, and it deserves more attention than it will get. In the two adult phase 3 studies, abrupt discontinuation after chronic administration "produced a very low degree of withdrawal symptoms that were indistinguishable from those produced by placebo." The label draws the conclusion explicitly: "This suggests that even though SIMTRIYO is a CNS stimulant, it does not produce physical dependence."

The label also notes that centanafadine may produce tolerance, in the standard boilerplate sense, without presenting data quantifying it.

Clinically this matters. A stimulant that can be stopped without a withdrawal syndrome is easier to discontinue, easier to interrupt for drug holidays, and safer in patients whose adherence is erratic. It is a real differentiator from amphetamine-class agents. It is just not the differentiator anyone was expecting.

Dual Boxed Warnings: A First in ADHD

Simtriyo carries two boxed warnings, and the combination is unprecedented among ADHD medications.

The suicidality warning derives from a specific finding: in the 6-week pediatric study, higher rates of suicidal ideation and behavior were reported in centanafadine-treated children aged 6 to 12 than in placebo-treated children. The label requires close monitoring of all pediatric patients 6 and older, especially during the initial months, and instructs prescribers to consider stopping the drug if suicidal ideation emerges.

From a child psychiatry standpoint, this is the label's most consequential feature for the youngest patients. The population in which the suicidality signal appeared — ages 6 to 12 — is the same population in which the rash signal appeared, and it is the population with the largest measured benefit. That is an uncomfortable set of facts to hold together in a single prescribing decision, and it means the informed-consent conversation for a 7-year-old starting Simtriyo is materially longer than the one for starting methylphenidate.

The Efficacy Data, With the Numbers

Approval rested on four 6-week randomized, double-blind, placebo-controlled trials: two pediatric (Studies 1 and 2) and two adult (Studies 3 and 4).

Children 6 to 12 Years (Study 1, NCT05428033)

480 patients aged 6 to 12 randomized 1:1:1 to weight-based equivalent of 280 mg, weight-based equivalent of 140 mg, or placebo. Mean age 9 years; 58% male; 27% Black or African American, 65% White, 31% Hispanic or Latino. Primary endpoint: change from baseline at Week 6 in ADHD-RS-5 total raw score.

Note the placebo response: 10.8 points of the 16.3-point improvement occurred in the placebo arm. The drug-attributable increment is 5.6 points on a scale with a baseline of 43.

Adolescents 13 to 17 Years (Study 2, NCT05257265)

459 patients randomized 1:1:1 to 140 mg, 280 mg, or placebo. Mean age 15; 59% male.

The adolescent placebo response was larger still: 14.2 of 18.5 points.

Adults (Studies 3 and 4, NCT03605680 and NCT03605836)

906 adults aged 18 to 55 randomized across two studies. Primary endpoint: change from baseline at Day 42 on the ADHD Investigator Symptom Rating Scale (AISRS).

Three features of the adult data deserve comment.

First, there is no dose-response relationship. In Study 3 the low dose outperformed the high dose (-3.2 versus -2.7); in Study 4 the high dose was marginally better (-4.4 versus -4.0). Averaged across both studies, dose does not predict benefit. That is a meaningful finding for titration: pushing an adult from 210 mg to 280 mg has no trial-based expectation of greater efficacy, only of greater adverse effects, since nausea, dry mouth, and decreased appetite all rose with dose.

Second, the confidence interval for the Study 3 high dose extends to -0.14. That is statistical significance achieved by a margin that would not survive much perturbation.

Third, and easy to miss: the adult studies used a different formulation of centanafadine, not the marketed Simtriyo capsule. The label states that low and high doses of that other formulation are expected to be equivalent to Simtriyo 210 mg and 280 mg respectively, but the adult indication rests on a pharmacokinetic bridge rather than on trials of the actual product being sold.

Putting the Effect Sizes in Context

Converting these to approximate standardized effect sizes puts centanafadine in roughly the 0.3 to 0.4 range. For reference, in comparable short-term trials methylphenidate and amphetamine-class stimulants generally produce standardized effect sizes near 0.8 to 1.0, while atomoxetine and viloxazine sit near 0.3 to 0.5.

Centanafadine, in other words, performs like a non-stimulant. It is scheduled like a stimulant. This is the crux of the drug's positioning problem, and no amount of first-in-class mechanism language dissolves it.

The caveat matters and I will state it plainly: these are cross-trial comparisons, not head-to-head data. No trial has compared centanafadine with methylphenidate, amphetamine, atomoxetine, or viloxazine. Trial populations, placebo responses, and rating instruments differ. But the gap between 0.35 and 0.9 is large enough that methodological noise is an insufficient explanation.

Dosing: Rigid by Design

Simtriyo is supplied as 140 mg, 210 mg, and 280 mg extended-release capsules, taken once daily in the morning, with or without food, at approximately the same time each day.

Capsules must not be cut, crushed, or chewed. They may be swallowed whole, or opened and the entire contents sprinkled over one tablespoon (15 mL) of applesauce or yogurt, or into one tablespoon of orange juice, consumed immediately and followed by water. The granules must not be chewed and the mixture must not be saved for later. The sprinkle option is a real practical advantage for younger children and for patients with pill-swallowing difficulty — a constraint I discuss at length in the review of newer ADHD formulations.

The Missing Lower Rung

Here is the dosing fact with the largest practical consequence, and it is buried in Section 2.2.

In both pediatric trials, the 140 mg dose and its weight-based equivalent failed to separate from placebo. The label states it directly for each study and then draws the conclusion: "The effectiveness of SIMTRIYO 140 mg once daily in patients aged 13 to 17 years and the weight-based equivalent dosage in patients aged 6 to 12 years was not established." It goes further — 210 mg once daily and its weight-based equivalents were never studied in patients aged 6 to 17 and are "not recommended."

For pediatric prescribing this removes the maneuver clinicians rely on most. Ordinarily, when a child develops tolerable-but-annoying side effects, you reduce the dose and often keep most of the benefit. With Simtriyo in a child, the weight band determines the dose, the dose below it has no demonstrated efficacy, and the intermediate dose is explicitly not recommended. There is no titration ladder — only an on-off switch. A child either tolerates the target dose or comes off the drug.

This is a genuine and underappreciated disadvantage relative to every stimulant on the market, all of which offer fine-grained dose adjustment, and relative to atomoxetine and viloxazine, both of which have multiple efficacious dose levels.

Adverse Reactions

The safety database comprises 608 pediatric patients aged 6 and older exposed in Studies 1 and 2 (394 for at least 6 months, 286 for 12 months or longer), and 586 adults exposed to the other centanafadine formulation in Studies 3 and 4 (422 for at least 6 months, 221 for 12 months or longer). That is a reasonable long-term exposure base for a new molecular entity.

Children 6 to 12 Years (adverse reactions in at least 2%, greater than placebo)

Adolescents 13 to 17 Years

Adults (pooled Studies 3 and 4)

The Rash Signal

Rash is the adverse reaction I would counsel on most explicitly, and it is the one least likely to appear in marketing materials. In children 6 to 12 it occurred in 9% on drug versus 0% on placebo — a clean signal with no background noise. The label's definition is broad, encompassing drug eruption and macular, maculopapular, morbilliform, and papular rash. Rash also appears in the label's list of the most common adverse reactions leading to discontinuation, alongside decreased appetite, nausea, and somnolence.

Separately, Warning 5.11 addresses allergic reactions due to the inactive ingredient FD&C Yellow No. 5 (tartrazine). Whether the tartrazine content contributes to the rash incidence is not addressed in the label, but the juxtaposition is notable.

For adolescents, the standout is decreased appetite at 15% versus 2% — comparable to what one sees with stimulants, and another reminder that the "non-stimulant tolerability profile" framing does not hold up.

Warnings, Contraindications, and Interactions

The warnings section reads like a stimulant label with serotonergic additions.

Contraindications: known hypersensitivity to centanafadine or excipients; current use or use within 14 days of an MAOI; pheochromocytoma or history of pheochromocytoma.

Assessment required before initiating: abuse and addiction risk; presence of cardiac disease; heart rate and blood pressure; risk of developing a manic episode; family history of tics or Tourette's syndrome, with clinical evaluation for motor or verbal tics.

Warnings and precautions:

• Serious cardiac disease — avoid in structural cardiac abnormalities, cardiomyopathy, serious arrhythmia, coronary artery disease.
• Increased blood pressure and heart rate — assess after dose increases and periodically. Tachycardia occurred in 2% of adults at the high dose. At twice the maximum recommended dose, clinically significant QTc prolongation was not observed.
• Psychiatric adverse reactions — consider discontinuation if new psychotic or manic symptoms occur.
• Hypersensitivity reactions — anaphylaxis and angioedema have been reported.
• Long-term growth suppression in children — monitor height, weight, BMI, and linear growth; consider treatment interruption if growth falters. The label notes that children under 6 had a higher incidence of weight loss, which is the stated reason for the age and 20 kg weight floors.
• Peripheral vasculopathy including Raynaud's phenomenon — assess digital changes; consider rheumatology referral.
• Serotonin syndrome — a risk unique among ADHD agents, given the serotonergic reuptake inhibition.
• Motor and verbal tics, worsening of Tourette's syndrome — monitor regularly.

Drug interactions worth committing to memory:

• Alcohol — avoid at the same time as, and for at least two hours after, dosing. This is an unusual and specific instruction, and it will matter for adolescents and young adults.
• CYP1A2 substrates — monitor for adverse reactions; consider reducing the substrate dose.
• Other CNS stimulants — monitor for cardiovascular adverse reactions. The implication is that Simtriyo may be co-prescribed with a stimulant, but the label offers no efficacy data for that combination.
• Serotonergic drugs — serotonin syndrome risk. Relevant given how many ADHD patients carry comorbid depression or anxiety and take an SSRI or SNRI.

Simtriyo is not recommended in severe hepatic impairment.

Where Centanafadine Actually Fits

My reading of the label is unflattering in several specifics. But the conclusion I draw from it is not "why bother" — it is that centanafadine is a mid-potency option arriving in a field that genuinely needs a wider range of potencies, and that its value depends almost entirely on which patient you put it in front of.

Potency Is a Range, Not a Verdict

One early commentary framed this drug as having stimulant-like side effects without stimulant-like efficacy — so why bother. That is not wrong on the facts, but it treats adverse effects as a yes-or-no property. They are not. What matters clinically is severity, likelihood, and how many patients actually get one.

Every agent we use for ADHD acts on dopamine and norepinephrine in some fashion, and this one adds serotonin. All of them can suppress appetite and disturb sleep. Bupropion can affect sleep. The question is never whether a drug can cause insomnia; it is whether it causes insomnia the way short-acting amphetamine does. It does not.

Amphetamine is the most effective agent we have for reducing ADHD symptoms, and methylphenidate is next; 80 to 90% of patients who take one get substantial reduction or resolution of symptoms. That potency is precisely why they carry the adverse-effect burden they do. The mechanism driving the benefit is the mechanism driving the side effects — they are not independent, and there is no free lunch. A drug with roughly half the effect size should be expected to carry roughly proportionally less of the same burden, and centanafadine's own adverse-event profile is consistent with that.

If amphetamine is a jackhammer, the field has been short of mallets. Not every patient needs the jackhammer.

The Population Has Changed

This is the part I think most of the launch commentary has missed, in both directions.

ADHD's diagnostic boundary has moved repeatedly — minimal brain dysfunction, then attention deficit disorder with and without hyperactivity, then ADHD — because we have no biomarker and are still working out what the construct contains. Each widening has the same structural consequence: the narrow definition captures the most severely affected patients, and the patients added at the margin are, on average, less severely affected than the ones already inside.

Prevalence today runs somewhere around 7.5 to 9% in children and 3 to 4.5% in adults, and symptoms attenuate with age. More people are presenting, and a growing share of them have moderate rather than severe illness. For that group, maximal pharmacologic potency is not obviously the goal, and the adverse-effect cost of achieving it is less obviously worth paying. A drug whose effect size sits alongside bupropion and atomoxetine is a reasonable match for the patients who are actually walking in.

Access Is a Clinical Variable, Not a Footnote

Any comparison that treats stimulants as freely available is describing a world I do not practice in.

I recently wrote a prescription for generic long-acting methylphenidate — a medication that has existed for as long as I have been in practice — and the patient did not physically have it in hand for 21 days, with the patient, me, and the pharmacist all actively working the problem. Another family has been unable to fill for a month and a half. This is New York City, not a rural pharmacy desert.

The mechanics are structural rather than temporary. The DEA caps how much manufacturers may produce. Most of these medications are generic, so margins are thin while the regulatory burden is heavy, which leaves manufacturers with little incentive to expand output. The shortage that began around the pandemic keeps appearing to resolve and then recurring.

What remains reliably available is often short-acting amphetamine, which is my least favourite option to prescribe: multiple doses a day, an unpleasant offset, the highest likelihood of insomnia, and — of all the stimulants — the one whose misuse potential I would actually worry about. Meanwhile prior authorizations for ADHD medication have increased sharply.

So "the generic stimulant is cheaper and stronger" is true on paper and frequently irrelevant at the pharmacy counter. An effective unscheduled or lightly scheduled option has practical value that its effect size alone does not capture.

The Serotonin Question, Answered Honestly in Two Parts

First, the skeptical half. I am not aware of meaningful evidence that acting on serotonin does anything directly for ADHD symptoms. Nobody believes SSRIs treat ADHD, and serotonin reuptake inhibition is substantially what this mechanism is. As a direct explanation for symptom improvement, I would discount it.

Now the half that may actually matter. Roughly three-quarters of people with ADHD carry a major psychiatric comorbidity, and the longer someone has had ADHD, the higher the likelihood of secondary depression or anxiety. In an adult ADHD practice, the patient with no mood or anxiety comorbidity is the exception, not the rule. If a single agent could cover both, that would spare a great many patients a second prescription. That is a genuinely interesting hypothesis, and it is the one I would most like to see tested.

It has not been tested. The pivotal trials excluded patients in a current major depressive episode and excluded anxiety severe enough to matter — which is to say they excluded exactly the population in whom the serotonergic claim would be evaluable. The phase 3b trial in ADHD with comorbid anxiety is the first real attempt, it remains unpublished, and its anxiety effect was small. Until that reads out properly, the comorbidity rationale is a reason to be curious, not a reason to prescribe preferentially.

What an Approval Does and Does Not Tell You

Two interpretive points worth holding onto, because they apply to every new approval and are routinely misread.

The FDA is not answering the question clinicians are asking. Its function here is to establish that a drug is acceptably safe, not to establish that it is effective relative to what we already have or that it improves patients' lives. If comparative efficacy were the standard, approval would require an active comparator rather than placebo. An approval is a green light to start looking for appropriate patients and see how they do — not a finding that the drug is competitive.

Every number in the label is an average. Mean points dropped on a rating scale, and the percentage of patients reporting a given adverse event, are aggregates across heterogeneous groups. Individual variation is substantial. Some patients will respond well to a drug with a modest mean effect size and some will not respond to a strong one, and a group mean does not tell you which patient is in front of you.

This also connects to a broader shift in psychiatry that I think is overdue: away from symptom reduction as the endpoint and toward whether the patient's life is better. Untreated ADHD is associated with poor academic attainment, divorce, incarceration, motor vehicle crashes, and accidental death, and treatment measurably reduces several of those — on-medication crash risk approaches that of people without ADHD. None of the centanafadine trials measured anything of that kind, which is a limitation of the evidence base rather than of the drug.

The Real Constraints

None of the above erases the specifics. The dual boxed warnings are a first for an ADHD medication. Rash ran 9% versus 0% in children 6 to 12 and was a leading cause of discontinuation. There is no validated lower rung, because 140 mg failed in both pediatric trials. Dose-response is flat in adults, and the adult indication rests on a formulation bridge rather than a positive trial of the marketed capsule. Scheduling is undetermined. And it will be expensive with no generic, so at a population and healthcare-cost level this is not the efficient answer to anything — I fully expect to be completing prior authorizations for it.

My Practical Position

I am an oldie-but-a-goodie prescriber. Bupropion has been available for decades, is inexpensive and easy to obtain, and works well enough for ADHD that few clinicians would dispute it — despite never having earned an FDA indication for it. My threshold for reaching there is low, and it will stay low. Centanafadine is not displacing it, and it is not displacing a well-tolerated stimulant in a patient who is doing well on one.

But I expect to look for opportunities to use it, in four situations:

• Moderate rather than severe ADHD, where maximal potency is not the objective and the adverse-effect trade is unattractive.
• Patients who cannot reliably obtain a stimulant, or for whom the scheduled-substance logistics are themselves the barrier to treatment.
• As a potency-sparing partner. If it makes a real dent in symptoms and improves quality of life, a patient may need only occasional or smaller doses of the stronger agent. For someone whose limiting problem is stimulant adverse effects, that can matter more than the difference in effect size.
• Patients with a history of stimulant misuse, where the slower striatal dopamine rise and the absence of physical dependence are real properties, whatever the boxed warning says about abuse potential in general.

I would add one thing that does not appear in any trial. Patients ask for new medications, and I had several contact me about this one within a day of approval. Part of practising well is building a plan collaboratively, because a plan the patient actually endorses produces better outcomes than one imposed on them. A patient who is invested in trying a medication is more engaged with it, and that engagement is not clinically trivial. When someone has residual symptoms and a reasonable case for trying something new, "let us give it a shot and see how much it helps" is a defensible answer.

Before broader use I still want three things: post-marketing data on the pediatric suicidality signal in a larger sample; the DEA schedule, which determines real-world prescribing friction; and pricing.

On balance, I think it is a good thing that this space has opened up. Expanding the pharmacologic range was always the point — not because medication replaces the rest of treatment, but because it closes enough of the gap in sustained interest and reinforcement that a patient can engage with everything else we offer.

What Happens Next: DEA Scheduling

Simtriyo cannot be prescribed yet. Because the label establishes abuse potential, the DEA must assign a controlled substance schedule before marketing. Otsuka has indicated availability later in 2026.

One clarification, because the coverage has muddled it: every drug that reaches the market receives a scheduling determination. There is nothing unusual about "it has to be scheduled first." The only question is which schedule — and for this drug that question is consequential.

The schedule assigned will substantially shape the drug's clinical role. Schedule II would place it under the same constraints as methylphenidate and amphetamine — no refills, quantity limits, prescription-monitoring reporting — while offering half their efficacy, which would be close to fatal to its prospects. Schedule IV, the placement given to serdexmethylphenidate and to modafinil, would preserve a real advantage: refillable prescriptions, less DEA friction, easier telehealth prescribing. The abuse-liability data cut both ways, and the outcome is genuinely uncertain.

If I had to bet, I do not think it lands at Schedule II alongside methylphenidate and the amphetamines. The abuse-liability data are worse than Otsuka would like, but the striatal dopamine kinetics are slower than a stimulant's, there is no physical dependence, and the effect size is not in stimulant territory. A placement below Schedule II would preserve most of what makes the drug clinically useful. I will update this page when the schedule is announced.

What This Analysis Does Not Replace

This is an educational analysis of a newly published prescribing information document, written for clinicians and for informed patients and families. It is not medical advice and it is not a substitute for the full label or for individualized clinical judgment. Nothing here should be used to start, stop, or change a medication.

Anyone considering centanafadine should read the complete prescribing information and discuss it with their prescriber. My reading of effect sizes across drug classes relies on cross-trial comparison, which cannot substitute for head-to-head trials; where I have drawn conclusions beyond what the label states, I have tried to say so.

Frequently Asked Questions

Is Simtriyo (centanafadine) a stimulant or a non-stimulant?

A stimulant, per the label. The prescribing information describes Simtriyo as "a norepinephrine-dopamine-serotonin reuptake inhibitor and central nervous system stimulant." Its DEA schedule is pending, it carries a boxed warning for abuse, misuse, and addiction, and human abuse-liability studies found drug-liking scores not statistically significantly lower than amphetamine 40 mg at supratherapeutic doses. This contradicts years of coverage describing centanafadine as a novel non-stimulant, including my own earlier writing on this site. It is not a non-stimulant in the way atomoxetine, viloxazine, guanfacine, or clonidine are.

How effective is centanafadine compared with stimulants?

Considerably less, on the available evidence. Placebo-subtracted improvements were 5.6 points on the ADHD-RS-5 in children 6 to 12, 4.4 points in adolescents, and 2.7 to 4.4 points on the AISRS in adults — approximate standardized effect sizes of 0.3 to 0.4. Methylphenidate and amphetamine-class stimulants typically achieve 0.8 to 1.0 in comparable trials. Centanafadine's peer group is bupropion (0.46) and atomoxetine (0.45), with viloxazine nearby. No head-to-head trials exist, so this is cross-trial comparison, but the magnitude of the gap is hard to attribute to methodology alone. Being less potent is not the same as being useless — see the next question.

If centanafadine is less effective than stimulants, why use it at all?

Because potency is a range and not every patient needs the top of it. Adverse effects are not a yes-or-no property either — what matters is severity, likelihood, and how many patients actually get one. Every ADHD medication acts on dopamine and norepinephrine, so all of them can suppress appetite and disturb sleep; the question is whether they do it the way short-acting amphetamine does, and centanafadine does not. The mechanism producing benefit is the mechanism producing side effects, so a drug with roughly half the effect size should carry proportionally less of the same burden.

Three practical arguments follow. First, a growing share of patients presenting today have moderate rather than severe ADHD, and maximal potency is not obviously their goal. Second, stimulants are frequently difficult to obtain — DEA production quotas, thin generic margins, and a shortage that keeps recurring mean a prescription can take weeks to fill, and what is reliably in stock is often short-acting amphetamine, the least desirable option. Third, a moderately effective agent can be potency-sparing: if it improves symptoms and quality of life, a patient may need only occasional or smaller doses of a stronger drug, which for someone limited by stimulant adverse effects can matter more than the difference in effect size.

What is the dosing for Simtriyo?

140 mg, 210 mg, and 280 mg extended-release capsules, once daily in the morning, with or without food. Children 6 to 12 weighing at least 20 kg are dosed by weight: 140 mg for 20 to under 35 kg, 210 mg for 35 to 50 kg, 280 mg above 50 kg. Adolescents 13 to 17 receive 280 mg. Adults start at 210 mg and may go to a 280 mg maximum. Capsules may be opened and sprinkled on a tablespoon of applesauce, yogurt, or orange juice, consumed immediately; they must not be cut, crushed, or chewed. Note that 140 mg failed in both pediatric trials, so there is no validated lower dose for children and adolescents.

What are the boxed warnings?

Two. First, suicidal ideation and behaviors in pediatric patients 6 and older — higher rates occurred in centanafadine-treated children aged 6 to 12 than in those on placebo in a 6-week study. Second, abuse, misuse, and addiction, reflecting the CNS stimulant classification. Simtriyo is the first ADHD medication to carry both; stimulants carry the abuse warning without the suicidality warning, and atomoxetine and viloxazine carry the suicidality warning without the abuse warning.

What are the most common side effects?

Children 6 to 12: rash (9% versus 0% placebo) and decreased appetite (8% versus 3%). Adolescents: decreased appetite (15% versus 2%), nausea (10% versus 3%), rash (8% versus 1%), headache, abdominal pain. Adults at the high dose: headache (8%), decreased appetite (7%), insomnia (7%), nausea (7%), dry mouth (6%), diarrhea (5%). The rash signal in young children is the most distinctive finding — clean separation from placebo, and among the leading causes of discontinuation. The label also warns about allergic reactions to the inactive ingredient FD&C Yellow No. 5.

When will Simtriyo be available?

Later in 2026, after the DEA assigns a controlled substance schedule. The label lists both the schedule and the initial U.S. approval date as pending scheduling. Until that process completes, the drug cannot be marketed or prescribed.

Does centanafadine cause withdrawal?

Apparently not. In the two adult phase 3 studies, abrupt discontinuation after chronic dosing produced withdrawal symptoms indistinguishable from placebo. The label concludes that despite being a CNS stimulant, Simtriyo "does not produce physical dependence." The label separately notes that tolerance may develop, without quantifying it. This is the drug's clearest advantage over amphetamine-class agents.

Who is actually a good candidate for centanafadine?

Four groups, in my view. Patients with moderate rather than severe ADHD, where maximal potency is not the objective. Patients who cannot reliably obtain a stimulant, or for whom controlled-substance logistics are themselves the barrier to being treated. Patients where it can act as a potency-sparing partner, leaving them needing only occasional or smaller doses of a stronger agent. And patients with a history of stimulant misuse, where the slower striatal dopamine rise and the absence of physical dependence are real properties.

Two label features are genuine advantages in any of those groups: abrupt discontinuation in adults produced withdrawal symptoms indistinguishable from placebo, and the capsule can be sprinkled for children who cannot swallow pills. What centanafadine does not offer is the thing clinicians most wanted — stimulant-level efficacy without controlled substance status. It has neither. That makes it a useful mid-potency option rather than a first-line or second-line agent.

Can centanafadine be combined with a stimulant?

The label contemplates it without endorsing it. The drug interactions section instructs prescribers to monitor for cardiovascular adverse reactions with concomitant CNS stimulants, and to consider reducing the stimulant dose or discontinuing one agent if such reactions occur. No efficacy data for the combination are presented. Given that both agents raise heart rate and blood pressure, and that neither combination efficacy nor combination safety has been formally studied, I would regard this as a specialist decision requiring cardiovascular monitoring.

That said, the potency-sparing scenario is the combination use I find most clinically interesting: a patient stabilized partly on centanafadine who then needs only occasional or lower doses of a stimulant. For a patient whose limiting problem is stimulant adverse effects, that trade can be worth more than the difference in effect size. It is untested, so it belongs in careful individual practice with monitoring, not in a guideline.

Who should not take Simtriyo?

It is contraindicated with hypersensitivity to centanafadine or its excipients, with MAOI use or within 14 days of stopping an MAOI, and in pheochromocytoma or a history of it. It should be avoided in serious cardiac disease. It is not recommended in severe hepatic impairment, in children under 6, or in patients weighing under 20 kg. Caution is warranted with a personal or family history of tics or Tourette's syndrome, with bipolar disorder or mania risk, with serotonergic co-medication, and where growth suppression is already a concern.

Primary References

Further Reading

• The New ADHD Medications of 2024-2026 — the broader review this analysis updates, covering Qelbree, Azstarys, Onyda XR, and the reformulation landscape
• ADHD Pharmacology and the Natural Course of Illness — companion review of the underlying drug classes and how treatment intersects with the course of ADHD across the lifespan
• Untreated ADHD: Adverse Outcomes — the population-level evidence for why effective pharmacological treatment matters
• Choosing Between Stimulants and Non-Stimulants — the decision framework centanafadine complicates
• Stimulants vs. Non-Stimulants — the foundational class-comparison framework
• ADHD Medication Side Effects — what to expect and how to manage common adverse effects
• ADHD Medication Titration — why the absence of a validated lower dose matters so much in pediatric prescribing
• ADHD Medications and Cardiovascular Safety — relevant to the blood pressure and heart rate monitoring Simtriyo requires
• ADHD, Tics, and Tourette's Syndrome — context for the label's tic screening requirement
• Medication Titration and Dosing in Children — the pediatric dose-adjustment practices Simtriyo does not accommodate
• ADHD Drug Holidays — where the absence of a withdrawal syndrome could be an advantage
• Stimulant Shortages, Insurance, and Prior Authorization — the access problems a truly unscheduled agent would have solved
• ADHD, Substance Use, and Protective Effects of Treatment — why abuse liability in an ADHD drug matters clinically
• ADHD Medication Tolerance — when medications appear to stop working
• ADHD Medication Guide — comprehensive reference on all currently used ADHD medications
• ADHD Psychiatrist NYC — evaluation and medication management for adults and adolescents with ADHD